Cholestatic liver diseases: An era of emerging therapies

Hrishikesh Samant, Wuttiporn Manatsathit, David Dies, Hosein Shokouh-Amiri, Gazi Zibari, Moheb Boktor, Jonathan Steve Alexander

Research output: Contribution to journalShort surveypeer-review

11 Scopus citations


Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease. Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid (UDCA), the current standard treatment for cholestatic liver disease. Important novel treatment targets now also include nuclear receptors involved in bile acid (BA) homoeostasis like farnesoid X receptor and G proteincoupled receptors e.g., the G-protein-coupled BA receptor "transmembrane G coupled receptor 5". Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA. In this review, we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.

Original languageEnglish (US)
Pages (from-to)1571-1581
Number of pages11
JournalWorld Journal of Clinical Cases
Issue number13
StatePublished - Jul 1 2019
Externally publishedYes


  • Bile acids
  • Cholestatic liver disease
  • Drug therapy
  • Nuclear receptor agonists

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Cholestatic liver diseases: An era of emerging therapies'. Together they form a unique fingerprint.

Cite this